ACE-Breast-02: a randomized phase III trial of ARX788 versus lapatinib plus capecitabine for HER2-positive advanced breast cancer
ACE-Breast-02:一项比较 ARX788 与拉帕替尼联合卡培他滨治疗 HER2 阳性晚期乳腺癌的随机 III 期试验
期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-025-02149-3
Hu, Xichun; Zhang, Qingyuan; Wang, Leiping; Zhang, Jian; Ouyang, Quchang; Wang, Xiaojia; Li, Wei; Xie, Weimin; Tong, Zhongsheng; Wang, Shusen; Xu, Faliang; Sun, Tao; Liu, Wei; Chen, Zhendong; Wu, Jinsheng; Wang, Ying; Wang, Haixia; Yan, Min; Wang, Xinshuai; Wang, Jingfen; Cao, Feilin; Du, Yingying; Zhang, Yongqiang; Chen, Lilin; Lu, Ping; Sun, Sanyuan; Zhang, Ruiwen; Zang, Aimin; Nie, Xiuqing; Lei, Yuan